Company intelligence / Profile preview

Wuhan Qirui Pharmaceutical

Ownership: Private
Employees: ~1600
Development stage: Other

Overview

Wuhan Qirui Pharmaceutical has developed and commercialized fasudil mesylate for the treatment of intracranial vasospasm. The company has a history of innovative research in multiple therapeutic areas and operates across the full pharmaceutical value chain from R&D to manufacturing. It holds GMP certification for key products such as fasudil mesylate. The pipeline includes both approved drugs and ongoing clinical development programs.

Therapeutic areas: NeurologyPulmonologyInfectious DiseasesGastroenterologyImmunologyCardiovascular
Modalities: Small molecule
Industry: Biotech

Partnerships

Joint laboratory with Tongji University established in 2007

Beyond the preview

Go deeper on Wuhan Qirui Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wuhan Qirui Pharmaceutical.

Explore the full profile